FDA approves gefurulimab for myasthenia gravis
-
By
-
Mouj Hijazi
-
November 16, 2026
-
3 min
Clinical Report: FDA approves gefurulimab for myasthenia gravis
Overview
The FDA approved gefurulimab-gaks (Klygefa) for adults with anti-AChR antibody-positive generalized myasthenia gravis (gMG). In the 26-week PREVAIL trial, gefurulimab improved MG-ADL and Quantitative Myasthenia Gravis scores compared with placebo; treatment is administered subcutaneously once weekly and carries a boxed warning for serious meningococcal infections.
Background
Generalized myasthenia gravis is a chronic autoimmune disease characterized by muscle weakness. In anti-AChR antibody-positive disease, complement activation contributes to neuromuscular junction damage. Gefurulimab is a dual-binding nanobody that inhibits complement protein C5 and prevents formation of the membrane attack complex. Its binding to serum albumin extends its half-life, supporting weekly subcutaneous administration.
Data Highlights
| PREVAIL measure | Gefurulimab | Placebo |
|---|---|---|
| Participants | 131 | 129 |
| MG-ADL change at week 26 | Improvement of 4.2 points | Improvement of 2.6 points |
| Quantitative Myasthenia Gravis score change | Improvement of 4.5 points | Improvement of 2.4 points |
| At least 3-point MG-ADL improvement at week 26 | 65.5% | 52.2% |
| Injection-site reactions | 12% | 3% |
| Back pain | 8% | 2% |
| Vomiting | 5% | 1% |
PREVAIL was a 26-week, randomized, double-blind, placebo-controlled phase 3 trial conducted across 20 countries. The primary endpoint was change from baseline in MG-ADL total score at week 26; the reported treatment difference was −1.6 points.
Key Findings
- The FDA approval covers adults with anti-AChR antibody-positive gMG.
- PREVAIL enrolled 260 adults with MGFA class II–IV disease and baseline MG-ADL scores of at least 5; participants continued eligible background therapies at stable doses.
- The primary endpoint, MG-ADL change at week 26, improved by 4.2 points with gefurulimab and 2.6 points with placebo, with a reported treatment difference of −1.6 points.
- The key secondary Quantitative Myasthenia Gravis score improved by 4.5 points with gefurulimab and 2.4 points with placebo; AstraZeneca reported improvement beginning at week 1 and maintained through week 26.
- The prescribing information specifies a day-1 loading dose followed by weekly dosing: below 80 kg, 600 mg then 300 mg from day 8; at least 80 kg, 900 mg then 600 mg weekly.
- The label has a boxed warning for serious meningococcal infections, requires meningococcal vaccination at least 2 weeks before treatment, and restricts access through a REMS. Related guidance and consensus sources describe complement inhibitors among targeted treatment options for appropriate AChR-positive gMG populations.
Clinical Implications
Patients or caregivers may administer gefurulimab after appropriate training, using an autoinjector or prefilled syringe. Prescribers must assess meningococcal vaccination status and follow the boxed warning and REMS requirements; antibacterial prophylaxis is specified when urgent treatment is needed in patients not up to date with vaccination.
Conclusion
Gefurulimab is a newly FDA-approved weekly subcutaneous C5 inhibitor for adults with anti-AChR antibody-positive gMG. PREVAIL reported improvements in MG-ADL and Quantitative Myasthenia Gravis scores versus placebo, alongside label-mandated meningococcal infection precautions.
Related Resources & Content
- AstraZeneca, FDA approval announcement, November 16 -- FDA approves gefurulimab-gaks (Klygefa) for adults with anti-AChR antibody-positive gMG
- US Food and Drug Administration, Prescribing Information, 2026 -- Gefurulimab-gaks (Klygefa) prescribing information
- JAMA Neurology, 2026 -- Efficacy and Safety of Gefurulimab in Generalized Myasthenia Gravis: The PREVAIL Phase 3 Randomized Clinical Trial
- International Consensus Guidance for Management of Myasthenia Gravis, 2021 -- 2020 Update
- Association of British Neurologists, Practical Neurology, 2025 -- Autoimmune myasthenia gravis management guidelines
- ophthalmology management — FDA Approves Uplizna for Adults Who Have Generalized Myasthenia Gravis
- MDSpire News — New Label Expansion in Generalized Myasthenia Gravis
- Ophthalmology Management — FDA Approves Uplizna for Adults Who Have Generalized Myasthenia Gravis
- International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update
- Association of British Neurologists autoimmune myasthenia gravis management guidelines (2025 update)
- Assessment of Gefurulimab's Safety and Effectiveness in Patients with Generalized Myasthenia Gravis: Results from the PREVAIL Phase 3 Trial
- International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update
- Association of British Neurologists (ABN) autoimmune myasthenia gravis management guidelines (2025 update)
- Comprehensive Care Goals in Myasthenia Gravis: Expert Consensus Recommendations Using the RAND/UCLA Appropriateness Method
- A Delphi consensus on integrating novel therapies into the management of generalized myasthenia gravis
- Myasthenia gravis - Symptoms, diagnosis and treatment | BMJ Best Practice US
- Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study
- CDR Clinical Review Report for Soliris
- Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis
- Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study
- SOLIRIS
- label
- HIGHLIGHTS OF PRESCRIBING INFORMATION
- AstraZeneca wins FDA approval for Klygefa | AZN SEC Filing - Form 6-K
- HIGHLIGHTS OF PRESCRIBING INFORMATION
Based on findings from:
FDA approves gefurulimab for myasthenia gravis
Mouj Hijazi. MDSpire News, 2026.
https://news.mdspire.com/neurology/articles/fda-approves-gefurulimab-for-myasthenia-gravis/
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.